See ritonavir + fluticasone.
The pharmacokinetics of fluticasone (cytochrome 3A4 metabolism, long half-life, bioavailability, volume of distribution, lipophilicity, etc.) can lead to accumulation in the presence of CYP3A4 inhibitors.
The accumulation of corticosteroids can cause Cushing's syndrome (moon face, excitation/insomnia, hypertension, increased appetite and weight, ease of doing bruising) and potentially a suppression of the hypothalamic-pituitary axis, which could lead to adrenal insufficiency. Several cases have been reported in the literature, and this in such a short time as 2 weeks.
A pharmacokinetic study demonstrated that ritonavir, a potent CYP 3A4 inhibitor, can increase fluticasone AUC up to 350-fold.
This interaction has been notably a Health Canada warning in 2004 and ritonavir monograph specifie that its association with fluticasone is a risk of serious side effects.
The safest corticosteroid is beclomethasone (Qvar) since its metabolism is mainly by an esterification mechanism.
Ref #2550 and #2551 : A cross-sectional study (n = 11 783) suggests lower prevalence of adrenal insufficiency with beclomethasone than with other corticosteroids currently available on the market. Pharmacokinetic studies with beclomethasone and ritonavir or combination darunavir/ritonavir demonstrated that there were no clinically significant pharmacokinetic interactions. No variation of blood cortisol have been observed.
Fluticasone should not be stopped without consultation with a physician. If the axis hypothalamo-hypophyseal is eliminated, stopping suddenly fluticasone can lead to signs and symptoms of adrenal incapacity. It is recommended to decrease slowly the corticosteroid to avoid the symptoms of craving (fatigue, loss of weight, intoxications, weakness, low postural blood pressure and acute adrenal crisis). Plasma cortisol and ACTH test will document the presence or absence of adrenal insufficiency.
Saberi P, Phengrasamy T and Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors : a review of pharmacokinetics, case reports and clinical management. HIV medicine 2013 : 1-11.
St Germain RM, Yigit S, Wells L, Giratto JE, Salazar JC. Cushing’s syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent. AIDS Patient Care STDs 2007; 21:
Daveluy A, Raignoux C, Miremont-Salame G et al. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol 2009; 65: 743–745.
Mahlab-Guri K, Asher I, Gradstein S et al. Inhaled fluticasone causes iatrogenic cushing’s syndrome in patients treated with Ritonavir. J Asthma 2011; 48: 860–863.
Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing’s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010;47(7):830–1.
Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab. J Clin Endocrinol Metab 2005; 90: 4394-8.
Rouanet I, Peyiere H, Mauboussin JM, and Vincent D. Cushing's syndrome in a patient treated with lopinavir/ritonavir and inhaled fluticasone. HIV Med 2003;4(4):149-150.
Spruyt S, Vlieghe E, Bomans P, Moerman F, Colebunders R, Van den Ende J. Inhaled corticosteroids in persons with HIV infection: not that harmless. Acta Clinical Belgica, 2012; 67-2.
Valin N, De Castro N, Garrait V, et al. Cushing’s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic). 2009;8(2):113–21
Pessanha TM, Mauricio J, Campos S et al. Iatrogenic Cushing’s syndrome in an adolescent with AIDS on ritonavir and inhaled fluticasone. Case report and literature review. AIDS 2007; 21: 529–538.
Jain L. Iatrogenic Cushing’s as a recognised complication of
concomitant ritonavir and steroid use: A systematic review
of cases and recommendations for clinical practice. BHIVA 2014, Liverpool UK, 1-4 april 2014, abstract P177.
Santé Canada. Renseignements importants sur l'innocuité-interaction médicamenteuse entre le propionate de fluticasone (Flonase /Flovent /Advair ) et le ritonavir (Norvir /Kaletra). Disponible : http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14261a-fra.php. Publié 22 janvier 2004. Consulté le 18 juin 2015.
Fluticasone (Flovent HFA/Diskus), GlaxoSmithKline, Ontario, Canada, 26 avril 2018.
Ritonavir (Norvir), Corporation AbbVie, Quebec, Canada, 5 juillet 2021.
Molimard M, Girodet PO, Pollet C et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf 2008; 31(9): 769-774.
Boyd A, Hadigan C, Pau A. Darunavir/ritonavir Does Not Significantly Increase Plasma Concentrations of Orally Inhaled Beclomethasone in Healthy Volunteers. Conference on Retroviruses and Opportunistic Infections, Seattle, 2012, Abstract 611.
Boyd A, Penzak S, Nieman L et al. Co-administration of Orally Inhaled Beclomethasone Dipropionate and HIV Protease Inhibitor Does Not Significantly Alter Adrenal Function in Healthy Volunteers. Conference on Retroviruses and Opportunistic Infections, Seattle, 2012, Abstract 610.
Lougheed MD, Lemiere C, Ducharme F et al. Canadien Thoracic Society 2012 guideline update: Diagnosis and management of athsma in preschoolers, children and adults. Can Respir J 2012; 19 (2): 127-164.
Johnson SR, Marion AA, Vrchoticky T, et al. Cushing’s syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006;148:386-8.
Ritonavir (Norvir), Prescribing Information, Abbvie Inc., IL USA, October 2020.
Clevenbergh P, Corcostegui M, Gerard D,et al. Iatrogenic Cushing's Syndrome in an HIV-Infected Patient Treated with Inhaled Corticosteroids (Fluticasone Propionate) and Low Dose Ritonavir Enhanced PI Containing Regimen. J Infect 2002 Apr; 44(3): 194-5.
Hillebrand-Haverkort ME, Prummel MF, and ten Veen JH. Ritonavir induced Cushing’s syndrome in a patient treated with nasal fluticasone. AIDS 1999;13(13):1803 [Letter]
Brus R. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Arch Intern Med 1999;159:1903-1908.
Gillett MJ, Cameron PU, Nguyen HV, et al. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 2005;19(7):740-741.
Woods DR, Arun CS, Corris PA, and Perros P. Cushing’s syndrome without excess cortisol. Br Med J 2006; 332:469-470.
Le Roux CW, Beckles MA, Besser GM, et al. Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy. HIV Medicine 2001; 2(2): 133.
Li AB. Ritonavir and fluticasone: Beware of this potentially fatal combination. J Pediatr 2006; 148:294-295.
Chen F, Kearney T, Robinson S, et al. Cushing’s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999;75:274.
Soldatos G, Sztal-Mazer S, Woolley I and Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir–fluticasone interaction. Intern Med J 2005; 35: 67-72.
Foisy MM, Yakiwchuk, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med, 2008, 9(6): 389-396.
Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res, 2009, 15(12): 4228-4233.
Bhumbra NA, Sahloff EG, Oehrtman SJ and Horner JM. Exogenous Cushing Syndrome with Inhaled Fluticasone in a Child Receiving Lopinavir/Ritonavir. The Annals of Pharmacotherapy 2007;41 : 1306-9.
Nocent C, Raherison C, Dupon M, Taytard A. Unexpected effects of inhaled
fluticasone in an HIV patient with asthma. J Asthma 2004;41:793-5.
Arrington-Sanders R, Hutton N, Siberry GK. Ritonavir–fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 2006;25:1044-1048.
Donnelly, R, Williams, K, Baker, AB et al. Effects of budesonide and fluticasone on 24 hour plasma cortisol. A dose response study. Am J Respir Crit Care Med 1997; 156, 1746–1751.
Seymour N, Robinson M, Richardson D, Mohammed H, Williams D, et al. Prescribing intranasal steroids in HIV-positive patients: systematic review of the literature. J Laryngol Otol . 2021 Sep; 135(9): 755-758.